Deals for AI discovery platforms and differentiated experimental candidates for obesity and solid tumors dominated the week.

AstraZeneca pays $40 million upfront to put insitro's AI platform to work on metabolic dysfunction-associated steatohepatitis ...

AstraZeneca agrees a $40m upfront deal with insitro to use AI in drug discovery for MASH and cardiomyopathies. Read more.

Indian scientists and biopharmaceutical firms are using artificial intelligence to identify promising drug candidates faster ...

By Patrick Wingrove LONDON, Oct 15 (Reuters) - AstraZeneca has teamed up with artificial intelligence biotech company insitro ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) snapped a three-day winning streak on Thursday, surging as much as 17.9 percent ...

AstraZeneca has entered into a strategic drug discovery collaboration and licensing agreement with insitro to use artificial intelligence to identify new drug targets and develop potential treatments ...

Biotechnology firm INmune Bio Inc. (NASDAQ: INMB) and photonic quantum developer Quantum Computing Inc. (NASDAQ: QUBT) have ...

Curitiba-based biotechnology company advances synthesized compounds into in vitro testing in Brazilian laboratories.

There has been another major milestone in the field of AI-driven drug discovery (AI drug discovery).I would like to organize ...

AstraZeneca partners with insitro on an AI drug discovery deal worth up to $1.86 billion targeting fatty liver disease and ...

The drugmaker will pay AI therapeutics company Insitro $40 million upfront and up to $1.46 billion subject to meeting targets ...